**Title:** Re-evaluating the evidence for fecal microbiota transplantation "super-donors" in inflammatory bowel disease

Short title: Re-evaluating FMT "super-donors"

Authors: Scott W. Olesen, PhD<sup>1,2</sup>; Ylaine Gerardin, PhD<sup>3</sup>

 OpenBiome, Cambridge, MA
 Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA
 Finch Therapeutics, Somerville, MA

# Correspondence

Scott Olesen 2067 Massachusetts Avenue Cambridge, MA 02140 solesen@openbiome.org

**Keywords**: fecal microbiota transplantation, inflammatory bowel disease, donor effect, super donor

Main text word count: 3880

- 1 SUMMARY (200 words)
- 2

3 **Background**: Fecal microbiota transplantation (FMT) is a recommended treatment for 4 recurrent *Clostridioides difficile* infection, and there is promise that FMT may be 5 effective for conditions like inflammatory bowel disease (IBD). Previous FMT clinical 6 trials have considered the possibility of a "donor effect", that is, that FMT material from 7 different donors has different clinical efficacies. 8 9 Aim & Methods: Here we re-evaluate evidence for donor effects in published FMT 10 clinical trials for IBD. 11 12 **Results:** In 7 of 9 published studies, no statistically significant donor effect was 13 detected when rigorously re-evaluating the original analyses. One study had statistically 14 significant separation of microbiota composition of pools of donor stool when stratified 15 by patient outcome. One study reported a significant effect but did not have underlying 16 data available for re-evaluation. When guantifying the uncertainty on the magnitude of 17 the donor effect, confidence intervals were large, including both zero donor effect and 18 very substantial donor effects. 19 20 **Conclusion**: Although we found very little evidence for donor effects, the existing data 21 also cannot rule out the possibility that donor effects are clinically important. Large 22 clinical trials prospectively designed to detect donor effects are likely necessary to 23 determine if donor effects are clinically relevant for IBD.

#### 24 INTRODUCTION

25

26 The human microbiome is increasingly understood to play a key role in health and 27 disease.<sup>1</sup> Fecal microbiota transplantation (FMT), the infusion of a healthy person's 28 stool into a patient, is one method for manipulating the gut microbiome.<sup>2</sup> FMT is recommended for treatment of recurrent *Clostridioides difficile* infection.<sup>3,4</sup> Although our 29 30 understanding of the specific mechanisms by which FMT cures C. difficile infection are 31 still developing, FMT is being investigated as a therapy for dozens of other microbiomerelated indications.<sup>2,5,6</sup> 32 33 34 A key challenge in identifying FMT's specific mechanism, or mechanisms, is the 35 complexity and diversity of human stool. Stool is a mixture of bacteria, viruses, fungi, 36 microbe-derived molecules, and host-derived molecules that varies enormously from person to person.<sup>7,8</sup> It has therefore been hypothesized that different stool donors, 37 38 different FMT material, or different matches of donors and recipients could have 39 different abilities to treat disease. This concept has been referred to with terms like "donor effect", "super-donor", and "super-stool".<sup>6,9-12</sup> 40 41 42 If FMT's efficacy varied widely across stools or donors, then rational selection of FMT 43 material based on biomarkers predictive of efficacy could improve the clinical practice of FMT.<sup>6,11,13,14</sup> Differences in FMT efficacy between stool donors or specific stools could 44 45 be also an important starting point for scientific investigations into the "active ingredient"

46 in FMT donations.<sup>11</sup> It is therefore important to quantify the extent of donor variability in
47 indications where FMT is a promising treatment.

48

Although there is little evidence of a donor effect in the context of *C. difficile* infection,<sup>15–</sup>
<sup>17</sup> the condition for which the use of FMT is best studied, multiple studies using FMT to
treat inflammatory disease have tested for donor effects,<sup>2,9,10,18–24</sup> and some have
reported statistically significant results. However, there are reasons to be skeptical of
the clinical implications of these intriguing findings.

54

First, a previous report<sup>25</sup> found that, in simulations of clinical trials, studies with numbers of patients similar to the number used in extant studies would be unlikely to discover a donor effect unless it were very large. Statistically significant results from underpowered studies may represent discoveries of real effects, but they may also represent false positives.

60

Second, in all previous studies, identifying a donor effect was a *post hoc* analysis, and
in no case was multiple hypothesis correction, a critical methodology in *post hoc*analyses, employed. In addition, we show herein that, in at least two previous reports,
the specifics of the clinical design require adjustments to the statistical tests used to
avoid inflating the apparent evidence for a donor effect.

66

67 Third, previous reports mostly analyzed donor effects by testing null hypotheses that are

biologically unlikely: either that all donors produce stool with exactly equal clinical

69 efficacy, or that particular features of stool, like its bacterial community diversity, are 70 completely unrelated to clinical efficacy. However, it is highly improbable that all stool 71 has precisely the same therapeutic effect: if a study is large enough, the difference 72 between two donors' treatment efficacies would almost certainly become statistically 73 significant as the number of treated patients increases. We therefore propose that, 74 rather than merely asking if donor effects exist or not, we should ask about the 75 magnitude of the donor effect and whether it is clinically relevant. In other words, rather 76 than merely testing for the statistical significance of donor effects, we should also assess effect sizes.<sup>26</sup> 77

78

Here we re-evaluate the existing evidence for donor effects and discuss the implications of that evidence for clinical trial design and clinical practice. First, we establish an ontology of the various concepts referred to as "donor effects". Second, we lay out a rigorous framework for identifying and quantifying donor effects. Third, we re-evaluate the existing literature using the conceptual ontology and the rigorous framework. Finally, we discuss the implications of this re-evaluation for future FMT research in IBD.

86

#### 87 METHODS

88

#### 89 Distinguishing types of stool superiority

90 Discussions of "super-donors" and "super-stool" have suggested that stool might be

91 superior in at least 4 distinct but conceptually related senses. To avoid confusion in our

92 re-evaluation of the evidence for donor effects, we distinguish between these definitions93 of stool superiority:

94

Donor superiority, in which particular donors are associated with better clinical outcomes for the recipient patients. For example, Moayyedi *et al.*<sup>18</sup> tested
 whether a particular donor ("donor B") was associated with better patient outcomes, compared to the other donors.

99 2. Donor characteristic superiority, in which donors with particular characteristics
100 are associated with better outcomes. For example, donor age, diet, and host
101 genetics have been suggested as potential factors in donor superiority.<sup>10,24,27</sup>

Material characteristic superiority, in which stool donations, pools of stool, or
 other fecal microbiota preparations that have some particular characteristic are
 associated with better outcomes. For example, Vermeire *et al.*<sup>28</sup> tested whether
 stools with higher bacterial diversity are associated with better outcomes.

 Donor-recipient match superiority, in which certain combinations of donors and recipients are associated with better outcomes,<sup>9,10,21,29</sup> analogous to how donors' and recipients' blood types are matched for blood transfusions. For example, FMT studies have tested whether stool from "related" donors,<sup>30</sup> typically defined

110 as first-degree relatives but also sometimes including spouses or partners, is

associated with better or worse patient outcomes.

112

113 These types of superiority are conceptually related and not mutually exclusive. For

example, imagine it were the case that female donors were associated with better

115 patient outcomes than male donors, consistent with definition 2, "donor characteristic 116 superiority". However, because donors have a clinical effect on the patient only via their 117 donation, sex of donor cannot be the molecular mechanism by which some donations 118 are more efficacious than others. It would have to be that sex determined or correlated 119 with some component of the stool that made those donations more effective. In other 120 words, there must be an underlying "material characteristic superiority", definition 3, that 121 correlates with donor sex. By a similar argument, even if donor-recipient match 122 superiority is the most accurate model, simpler types of superiority may be more parsimonious.<sup>12</sup> 123

124

## 125 Identifying and quantifying donor effects

126 We used a two-step framework for characterizing donor effects. First, we used statistical 127 tests to characterize the strength of the evidence for the reported type of donor effect. 128 Statistics were computed using the R programming language<sup>31</sup> (version 3.6.0). To test 129 the hypothesis that there is any difference in efficacy between donors (or pools of 130 donors), we used the Fisher-Freeman-Halton test (function fisher.test) on 2 × D 131 contingency tables, where D is the number of donors (or pools). For  $2 \times 2$  contingency 132 tables (e.g., to test if one donor has a different treatment efficacy than all the others), we used Fisher's exact test (function exact2x2)<sup>32</sup> and the mid-p value to prevent the tests 133 from being overly conservative.<sup>33</sup> To test for material (i.e., donation or pool) 134 135 characteristic superiority, we used the Mann-Whitney U test (*wilcox.test*) or Kruskal-136 Wallis test (kruskal.test). When 16S rRNA gut microbiota composition data were

available (see below), we tested for separation in donor microbiota compositions using
 PERMANOVA<sup>34</sup> (function *Adonis* in the R *vegan* package).<sup>35</sup>

139

140 Second, whether or not an effect was detected, we use a random effect logistic 141 regression (function *glmer* in the R *lme4* package)<sup>36</sup> to quantify the effect size. The 142 regression model assumes that the log odds of the efficacy of different donors (or pools 143 of stool) is Gaussian distributed. The regression returns the standard deviation of that 144 distribution, which is a measure of the "spread" in donors' efficacies. For clarity, we 145 convert the regression's estimates into the absolute difference in efficacy rates between 146 a 90th percentile donor (a very high quality donor) and a 10th percentile donor (a poor 147 donor). For example, an effect size of 30 percentage points means that, if a low quality 148 donor is 10% efficacious, then a high quality donor would be 40% efficacious.

149

#### 150 Studies re-analyzed

151 In the re-analysis, we included interventional FMT clinical studies that tested the 152 hypothesis that one donor or donation characteristic was associated with improved IBD 153 patient outcomes. Studies were identified using citations from an existing systematic 154 review,<sup>21</sup> narrative review,<sup>10</sup> and expert opinion.<sup>6</sup> For each study, we considered only a 155 single dichotomous outcome, whether a patient achieved the trial's primary clinical 156 endpoint. When 16S rRNA gut microbiota composition data were available, we tested for associations between donor material  $\alpha$ -diversity and patient outcomes, <sup>23,24,28</sup> since 157 158 part of the motivation for using pools of stool from multiple donors is the hypothesis that 159 high bacterial diversity in FMT material is beneficial.<sup>13,19,29,37</sup> When possible, we also

searched for separation in the microbiota compositions of donors according to the
outcomes of their associated patients, following the example of Jacob *et al.*<sup>20</sup>

162

## 163 Microbiome data preparation

164 We re-analyzed raw 16S rRNA sequencing data from three studies (Kump et al., study 165 accession PRJEB11841; Jacob et al., accession PRJNA388210; Goyal et al., accession 166 PRJNA380944) using QIIME 2<sup>38</sup> (version 2019.7) and Deblur.<sup>39</sup> For Kump et al. and 167 Jacob et al., paired reads were joined (vsearch plugin, default parameters), quality 168 filtered (*quality-filter* plugin, default parameters), and denoised using Deblur (trim length 169 253 nucleotides, 1 minimum reads, otherwise default parameters). For Goyal et al., the 170 sequencing data was single-ended (no joining required) and the trim length was 150 171 nucleotides. Alpha-diversity was computed by down-sampling all samples to the 172 minimum number of denoised read counts across samples and then using the Shannon 173 metric (*diversity* plugin). When a donor had multiple associated samples, we associated 174 a single  $\alpha$ -diversity with each donor by computing the mean  $\alpha$ -diversity over that donor's 175 samples. Beta-diversity, used for the PERMANOVA tests, was computed with the Bray-176 Curtis metric. When a donor had multiple samples, we used only the first sample from 177 each donor.

178

### 179 Code and data availability

180 Computer code and underlying data to reproduce the results are online (DOI:

181 10.5281/zenodo.3780184, <u>https://www.github.com/openbiome/donor-effects</u>).

183

#### 184 **RESULTS**

185

186 The results of the re-evaluation of the evidence for a donor effect in IBD from a

187 selection of FMT clinical studies in summarized in Table 1.

188

# 189 Rossen et al. 2015

190 In this study,<sup>9</sup> 23 ulcerative colitis patients were treated with FMT. 17 patients received 191 stool from 1 of 15 donors; 6 patients received stool from 2 different donors. The 192 outcome was clinical remission and endoscopic response at 12 weeks. In the original 193 publication, the investigators reported on the performance of 3 donors (Table 2). There 194 was no evidence of a donor effect (mid-p > 0.05, Fisher's exact test) for any of the 3 195 donors. However, the study is small enough that the data are not inconsistent with large 196 variability between donors. For example, the upper 95% confidence interval on donor 197 A's odds ratio of successful patient outcome compared to all other donors is 29. In other 198 words, the data do not provide evidence of a donor effect, but they also cannot 199 definitively rule out a strong donor effect.

200

#### 201 Moayyedi et al. 2015

In this study,<sup>18</sup> 38 ulcerative colitis patients were treated with FMT. Each patient was
treated with stool from 1 of 6 donors. The outcome was remission at 7 weeks. Donors
were used according to an adaptive process, described in the original publication.
Briefly, at the start of the trial, patients were treated with stool from one of two donors (A

or B). Material from donor B then became unavailable, and patients were instead treated with stool from donor A or 1 of 4 other donors. At this point, donor B became available again, and "[t]he remaining participants allocated to active therapy all received FMT from donor B exclusively, as [the investigators] had not experienced any success with donor A". In the original study, donor B's performance (7 of 18 treated patients achieved the primary endpoint) was compared against all other donors (2 of 20 patients; odds ratio 5.5 [95% CI 1.0 to 44], mid-p = 0.048, Fisher's exact test).

213

214 In general, adaptive trial designs require special statistical methodologies.<sup>40</sup> To 215 investigate whether typical statistical tests like Fisher's exact test accurately measure 216 the statistical significance of the data collected in Moayyedi et al., we simulated a 217 simplified adaptive donor selection process. First, among the first 24 simulate patients, 218 use all 6 donors 4 times each. Then select the best-performing donor to treat all the 219 remaining 14 patients. Finally, compare the overall performance of this donor against all 220 the others. In these simulations, if all the donors are actually the same (i.e., with equal 221 probability 9/38 = 24% of a positive patient outcome), the probability of finding mid-p < 222 0.05 is 8.8% (8843 of 10,000 simulations; 95% CI 8.7% to 9.0%), nearly double the 223 value that would be expected if the test were accurate for that type of data (i.e., the 224 false positive rate, 5%). The intuitive explanation is that, if all donors are the same, the 225 selection process is merely setting aside donors who had "bad luck" on their first 226 patients, and they are not allowed to recover their performance with a run of "good luck" 227 later on. This is not a flaw of Fisher's exact test. Instead, it is problem of applying a 228 statistical test to data that do not meet the assumptions of the test.

229

Although the adaptive procedure that led to extensive use of donor B may have improved the probability of the trial's success,<sup>12</sup> the procedure was not pre-specified, making it impossible to rigorously determine the degree to which the observed results are consistent with all donors being identical, that is, whether donor B simply had a "lucky" initial run. Thus, the value mid-p = 0.05 reported above is inaccurately optimistic, and a p-value of 0.09 is a better representation of the likelihood of a donor having the kind of success observed in this trial.

237

238 Paramsothy et al. 2017

In this study,<sup>19</sup> 41 ulcerative colitis patients were randomized to receive blinded FMT.
Another 37 were randomized to placebo and later received open-label FMT. Each of the
78 patients received FMT from 1 of 21 pools of donors. Each pool included material
from 3 to 7 donors, out of 14 total donors. The outcome in this analysis was clinical
remission with endoscopic remission or response at 8 weeks after either the blinded or
open-label FMT.

245

The original publication compared the best performing individual donor against all the others (14 of 38 patients achieved the primary outcome, versus 7 of 40 assigned to other donors; odds ratio 2.7 [95% CI 0.96 to 8.2], mid-p = 0.06, Fisher's exact test). This result, although near mid-p = 0.05, is not convincing when subjected to multiple hypothesis correction, as there are 14 relevant hypotheses to be tested, one per donor (Bonferroni-corrected p = 1.0, Benjamini-Hochberg FDR = 0.78). In terms of pools of donors, there was also no evidence that any particular pool was associated with better outcomes (p = 0.76, Fisher-Freeman-Halton test on 2 × 21 table of patient outcomes by pool).

255

256 To develop an estimate of the strength of the donor effect, we used a logistic 257 regression, modeling the pool as a random effect. This model estimated that the 258 difference in efficacy between a very high quality pool (90th percentile in terms of 259 efficacy) and a poor pool (10th percentile) is exactly 0 percentage points (95% CI 0 to 260 46 percentage points). In other words, the regression's best estimate of the variation in 261 efficacy among pools is zero, even without applying any penalizations for model 262 complexity. Thus, similar to Rossen et al., the data do not provide evidence for a donor 263 effect, but they are also not inconsistent with a strong effect, since the upper confidence 264 limit on the strength of the donor effect is a 46 percentage point difference in efficacy 265 rate between high- and low-quality donors.

266

#### 267 Costello et al. 2019

In this study,<sup>37</sup> 38 ulcerative colitis patients received FMT from 1 of 11 pools. Each pool included stool from 3 or 4 donors, out of 19 total donors. The outcome was steroid-free remission at 8 weeks. Similar to Paramsothy *et al.*, there was no evidence of heterogeneity in patient outcomes by donor pool (p = 0.50, Fisher-Freeman-Halton test on 2 × 11 table) nor evidence of better outcomes for any particular donor (mid-p > 0.05for all donors, Fisher's exact test). Furthermore, a logistic regression estimated the difference between a very high quality pool (90th percentile in terms of efficacy) and low quality pool (10th percentile) as 0 percentage points but with a wide confidence interval(95% CI 0 to 74 percentage points).

277

#### 278 Jacob et al. 2017

279 In this study.<sup>20</sup> 20 ulcerative colitis patients received FMT from 1 of 6 pools. Each pool 280 included stool from 2 donors, out of 4 total donors. In this analysis, the outcome was 281 clinical response at 4 weeks. Curiously, although a test for differences in patient 282 outcomes by pool was statistically significant (Fisher-Freeman-Halton test on 2 × 6 283 table, p = 0.02), a test for differences in outcomes by donor was not (mid-p > 0.05 for all 284 4 donors, Fisher's exact test). A logistic regression estimated the difference in efficacy 285 between very high quality pools and low quality pools as very large (88 percentage 286 points) but not statistically significant (95% confidence interval 0 to 100 percentage 287 points).

288

289 There was no evidence for an association between patient outcomes and the bacterial 290 community  $\alpha$ -diversity of the pool they received (Figure 1a;  $\rho = 0.39$ , Mann-Whitney U 291 test). In fact, more diverse pools were associated with worse patient outcomes. In our 292 analysis, donor microbiota compositions also did not separate according to their 293 associated patient outcomes (Figure 1b; p = 0.077, PERMANOVA), while they did in the 294 original analysis (Figure 4C in that publication, p = 0.044), likely due to the differences in 295 the 16S rRNA sequencing data processing pipeline. Our analysis used de-noising and 296 the Bray-Curtis  $\beta$ -diversity metric, while Jacob *et al.* used 97% operational taxonomic 297 units and the UniFrac metric.

298

#### 299 Meta-analysis of pool studies

300 Paramsothy et al., Costello et al., and Jacob et al. have sufficiently similar designs and 301 the available data to allow a meta-analysis. A logistic regression on the combined data 302 from all three studies, with the study as a fixed effect, estimated the difference in 303 efficacy between very high quality pools and low quality pools as 41 percentage points 304 but not statistically significant (95% CI 0 to 88 percentage points). 305 306 Goyal *et al*. 2018 307 In this study,<sup>24</sup> 21 patients with inflammatory bowel disease (any of Crohn's disease, 308 ulcerative colitis, or indeterminate colitis) received FMT and were available for follow-up. 309 We used remission at 30 days as the outcome. Each patient received stool from a 310 different donor, precluding any test of donor superiority. However, 16S rRNA 311 sequencing was performed, allowing for an analysis of donation characteristic 312 superiority, similar to Jacob et al. above. Similar to that study, there was no evidence for 313 an association between patient outcomes and the  $\alpha$ -diversity (Figure 2a; p = 0.97. 314 Mann-Whitney U test) nor separation in donor microbiota (Figure 2b; p = 0.7, 315 PERMANOVA).

316

#### 317 Kump et al. 2017

In this study,<sup>23</sup> 17 ulcerative colitis patients received 5 FMTs from 1 of 14 donors. 12
donors were used in 1 patient, 1 donor was used in 2 patients, and 1 donor was used in
3 patients. As in Goyal *et al.*, this distribution of patients across donors does not permit

an assessment of donor superiority. However, like Jacob *et al.* and Goyal *et al.*, this
study tested whether increased α-diversity was associated with improved patient
outcomes.

324

We detected no difference in diversity by patient outcome (Figure 3a; p = 0.39, Kruskal-Wallis test; p > 0.05 for all 3 comparisons, Mann-Whitney *U* test), nor did we detect separation in donor microbiota according to associated patient outcomes (Figure 3b; p = 0.39, Kruskal-0.15, PERMANOVA).

329

330 The original publication reported statistically significant differences between the  $\alpha$ -331 diversity of the 16 available donor stool samples associated with the 4 patients who 332 achieved remission compared to the diversity of 12 available samples associated with 333 the 4 patients who did not respond to FMT. Our analysis has a different conclusion, 334 finding no support for a donor effect, principally because we analyzed the data as only 8 335 independent data points, that is, one data point for each patient (4 remission, 4 no 336 response). By contrast, Kump et al. analyzed the data as if there were 28 independent 337 data points, that is, one data point for each donation (12 associated with remission, 16 338 associated with no response). Using donations rather than patients to determine N is a statistical error known as "pseudoreplication".<sup>41</sup> Repeated measurements of the material 339 340 delivered to a patient do not constitute independent measures of the patient's outcome. 341 In other words, when testing for an association between patient outcomes and a 342 donation characteristic like  $\alpha$ -diversity, the weight of the evidence is determined by the 343 number of patient outcomes, not by the number of microbiome measurements.<sup>42</sup>

344

### 345 Vermeire et al. 2016

In this study,<sup>28</sup> 14 patients with inflammatory bowel disease (either of Crohn's disease or ulcerative colitis) received FMT, each from a different donor. The original study reported that the bacterial  $\alpha$ -diversity of donations varied by patient outcomes, that patients with successful outcomes received more bacterially diverse donations (Mann-Whitney *U* test, *p* = 0.012). However, the underlying bacterial sequencing data was not available for re-analysis.

352

# 353 Nishida et al. 2017

354 In this study,<sup>22</sup> 41 patients with ulcerative colitis received FMT, each from a different 355 donor. The outcome was clinical response at 8 weeks. The original study found no 356 difference in the  $\alpha$ -diversity of the stool from 7 donors whose patients met the primary 357 endpoint, compared to 19 donors whose patients did not (p = 0.69). The study also 358 tested whether the abundance of 10 taxa were differentially abundant among those two 359 groups of donors, finding p-values less than 0.05 for 2 of 9 taxa, neither of which is 360 statistically significant after Benjamini-Hochberg multiple hypothesis correction. The 361 underlying bacterial sequencing data was not available for re-analysis.

362

363

#### 364 **DISCUSSION**

365 In this study, we re-evaluated 9 studies that used FMT for IBD. In 7 of 9 cases, there 366 was no statistically significant evidence of a donor effect. In one of the remaining 367 studies (Jacob *et al.*), there was a statistically significant difference in efficacy by pool of 368 donor stool, but not by donor, nor by the  $\alpha$ -diversity of the stool or by donor microbiota 369 composition. We were unable to re-analyze the other study (Vermeire *et al.*) that 370 reported a statistically significant effect.

371

The major strengths of this study were the rigorous statistical approach used, which avoided pseudoreplication and misinterpretation of results from an adaptive trial design, and the uniformity of the re-analysis of the 16S rRNA microbiota composition data.

375

However, this study is also subject to two key limitations. First, our analysis considered only donor effects and made no reference to patient factors like disease history. Given the small sample sizes, adding patient factors as predictors would only decrease our ability to detect donor effects, which was contrary to our main aim. We do not mean to imply that all IBD patients are the same or should receive the same kind of treatment. In contrast, a principal conclusion from this study is that patient factors, not donor factors, are the main determinants of an FMT patient's clinical outcome.

383

Second, our analysis considered only dichotomous patient outcomes and a small
number of predictors, namely donors' identities (e.g., donor A vs. donor B), pools'
identities (pool A vs. pool B), 16S rRNA microbiota composition α-diversity, and
microbiota composition β-diversity. Previous work suggests that more proximal patient
biomarkers, like mucosal immune markers, are more likely to be able to detect donor

389	effects. <sup>25</sup> We caution, however, that attempts to find associations between every
390	conceivable donor factor, patient factor, and patient outcome risks " <i>p</i> -hacking". <sup>43</sup>
391	
392	Overall, we found only very weak evidence for donor effects. On the other hand, the
393	small size of these studies —relative to the number of patients required to reliably
394	detect a plausible donor effect <sup>25</sup> — means that the data cannot definitively rule out a
395	large donor effect. It therefore remains undetermined if differences between donors are
396	clinically relevant to FMT for IBD. We propose that larger studies, with careful biomarker
397	selection and transparent reporting of results, is the best direction forward to
398	characterizing the donor effect for FMT in IBD.
399	
400	
401	DECLARATIONS
402	
403	Acknowledgements
404	Sudarshan Paramsothy, Nadeem Kaakoush, and Rotem Sadovsky for assistance in
405	collecting the Paramsothy et al. data and for helpful conversations. Sam Costello for
406	assistance in collecting the Costello et al. data and for helpful conversations. Eric J.
407	Alm, Shrish Budree, Claire Duvallet, Justin O'Sullivan, Pratik Panchal, Marina Santiago,

Mark B. Smith, and Duane Wesemann for helpful conversations.

409

408

410 Authorship statement

- 411 SWO is the guarantor. SWO conceived the study, obtained data, performed the
- 412 analysis, and wrote the manuscript. YG obtained data; improved the analysis,
- 413 interpretation, and presentation of the results; and revised the manuscript. All authors
- 414 approved the final version of the manuscript.
- 415

# 416 Statement of interests

- 417 SWO is employed by OpenBiome. YG is employed by and owns stock options in Finch
- 418 Therapeutics. No specific funding was received for this work.

### 420 **REFERENCES**

- Marchesi, J. R. *et al.* The gut microbiota and host health: a new clinical frontier.
   *Gut* 65, 330–339 (2016).
- 423 2. Allegretti, J. R., Mullish, B. H., Kelly, C. & Fischer, M. The evolution of the use of
- 424 faecal microbiota transplantation and emerging therapeutic indications. *Lancet*
- 425 *(London, England)* **394**, 420–431 (2019).
- 426 3. McDonald, L. C. et al. Clinical Practice Guidelines for Clostridium difficile Infection
- 427 in Adults and Children: 2017 Update by the Infectious Diseases Society of
- 428 America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).
- 429 *Clin. Infect. Dis.* **66**, e1–e48 (2018).
- 430 4. Debast, S. B., Bauer, M. P. & Kuijper, E. J. European Society of Clinical
- 431 Microbiology and Infectious Diseases: Update of the Treatment Guidance
- 432 Document for Clostridium difficile Infection. *Clin. Microbiol. Infect.* 20, 1–26
  433 (2014).
- 434 5. Olesen, S. W., Panchal, P., Chen, J., Budree, S. & Osman, M. Global disparities
  435 in faecal microbiota transplantation research. *Lancet Gastroenterol. Hepatol.* 5,
  436 241 (2020).
- 437 6. Lopetuso, L. R. *et al.* Fecal transplantation for ulcerative colitis: current evidence
  438 and future applications. *Expert Opin. Biol. Ther.* **20**, 343–351 (2020).
- 439 7. David, L. A. *et al.* Diet rapidly and reproducibly alters the human gut microbiome.
  440 *Nature* 505, 559–563 (2014).
- 441 8. Turnbaugh, P. J. *et al.* The human microbiome project. *Nature* 449, 804–10
  442 (2007).

- 443 9. Rossen, N. G. *et al.* Findings From a Randomized Controlled Trial of Fecal
  444 Transplantation for Patients With Ulcerative Colitis. *Gastroenterology* 149, 110445 118.e4 (2015).
- 446 10. Wilson, B. C., Vatanen, T., Cutfield, W. S. & O'Sullivan, J. M. The Super-Donor
- 447 Phenomenon in Fecal Microbiota Transplantation. *Front. Cell. Infect. Microbiol.*
- 448 (2019) doi:10.3389/fcimb.2019.00002.
- 449 11. Olesen, S. W., Leier, M. M., Alm, E. J. & Kahn, S. A. Searching for superstool:
- 450 Maximizing the therapeutic potential of FMT. *Nature Reviews Gastroenterology*
- 451 *and Hepatology* (2018) doi:10.1038/s41575-018-0019-4.
- 452 12. Olesen, S. W., Gurry, T. & Alm, E. J. Designing fecal microbiota transplant trials
  453 that account for differences in donor stool efficacy. *Stat. Methods Med. Res.*
- 454 (2018) doi:10.1177/0962280216688502.
- 455 13. Duvallet, C. *et al.* Framework for rational donor selection in fecal microbiota
  456 transplant clinical trials. *PLoS One* **14**, e0222881 (2019).
- 457 14. Barnes, D. et al. Competitively Selected Donor Fecal Microbiota Transplantation.
- 458 *J. Pediatr. Gastroenterol. Nutr.* **67**, 185–187 (2018).
- 459 15. Osman, M., Abend, A., Panchal, P., Kassam, Z. & Budree, S. Does the Donor
- 460 Matter? Microbiome Sequencing to Evaluate Lower Donor Efficacy in Fecal
- 461 Microbiota Transplantation for Recurrent Clostridium Difficile Infection.
- 462 *Gastroenterology* **154**, S-25-S-26 (2018).
- 463 16. Ray, A. & Jones, C. Does the donor matter? Donor vs patient effects in the
- 464 outcome of a next-generation microbiota-based drug trial for recurrent Clostridium
- 465 difficile infection. *Future Microbiol.* **11**, 611–616 (2016).

466 17. Zuo, T. *et al.* Gut fungal dysbiosis correlates with reduced efficacy of fecal
467 microbiota transplantation in Clostridium difficile infection. *Nat. Commun.* 9, 3663

468 (2018).

- 469 18. Moayyedi, P. et al. Fecal Microbiota Transplantation Induces Remission in
- 470 Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.
- 471 *Gastroenterology* **149**, 102-109.e6 (2015).
- 472 19. Paramsothy, S. *et al.* Multidonor intensive faecal microbiota transplantation for
- 473 active ulcerative colitis: a randomised placebo-controlled trial. *Lancet* **389**, 1218–
- 474 1228 (2017).
- 475 20. Jacob, V. et al. Single Delivery of High-Diversity Fecal Microbiota Preparation by
- 476 Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active
  477 Ulcerative Colitis. *Inflamm. Bowel Dis.* 23, 903–911 (2017).
- 478 21. Paramsothy, S. et al. Faecal Microbiota Transplantation for Inflammatory Bowel
- 479 Disease: A Systematic Review and Meta-analysis. J. Crohn's Colitis 11, 1180–
- 480 1199 (2017).
- 481 22. Nishida, A. *et al.* Efficacy and safety of single fecal microbiota transplantation for
  482 Japanese patients with mild to moderately active ulcerative colitis. *J.*
- 483 *Gastroenterol.* **52**, 476–482 (2017).
- 484 23. Kump, P. et al. The taxonomic composition of the donor intestinal microbiota is a
- 485 major factor influencing the efficacy of faecal microbiota transplantation in therapy
- 486 refractory ulcerative colitis. *Aliment. Pharmacol. Ther.* **47**, 67–77 (2018).
- 487 24. Goyal, A. et al. Safety, Clinical Response, and Microbiome Findings Following
- 488 Fecal Microbiota Transplant in Children With Inflammatory Bowel Disease.

- 489 *Inflamm. Bowel Dis.* **24**, 410–421 (2018).
- 490 25. Olesen, S. W. Power calculations for detecting differences in efficacy of fecal
  491 microbiota donors. *medRxiv* (2020) doi:10.1101/2020.04.16.20068361.
- 492 26. Wasserstein, R. L., Schirm, A. L. & Lazar, N. A. Moving to a World Beyond "p <
- 493 0.05". *Am. Stat.* **73**, 1–19 (2019).
- 494 27. Budree, S. et al. The Association of Stool Donor Diet on Microbial Profile and
- 495 Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile
  496 Infection. *Gastroenterology* **152**, S630–S631 (2017).
- 497 28. Vermeire, S. et al. Donor Species Richness Determines Faecal Microbiota
- 498 Transplantation Success in Inflammatory Bowel Disease. *J. Crohn's Colitis* 10,
  499 387–394 (2016).
- 500 29. Kazerouni, A. & Wein, L. M. Exploring the Efficacy of Pooled Stools in Fecal
- 501 Microbiota Transplantation for Microbiota-Associated Chronic Diseases. *PLoS*
- 502 One **12**, e0163956 (2017).
- 503 30. Khanna, S. et al. Changes in microbial ecology after fecal microbiota
- 504 transplantation for recurrent C. difficile infection affected by underlying
- 505 inflammatory bowel disease. *Microbiome* **5**, 55 (2017).
- 506 31. R Core Team. R: A language and environment for statistical computing. (R
- 507 Foundation for Statistical Computing, 2019).
- 508 32. Fay, M. P. Confidence intervals that match Fisher's exact or Blaker's exact tests.
- 509 *Biostatistics* **11**, 373–374 (2010).
- 510 33. Mehta, C. R. & Hilton, J. F. Exact power of conditional and unconditional tests:
- 511 Going beyond the 2x2 contingency table. *Am. Stat.* (1993)

- 512 doi:10.1080/00031305.1993.10475946.
- 513 34. Anderson, M. J. A new method for non-parametric multivariate analysis of
  514 variance. *Austral Ecol.* 26, 32–46 (2001).
- 515 35. Oksanen, J. et al. vegan: Community Ecology Package. https://cran.r-
- 516 project.org/package=vegan (2019).
- 517 36. Bates, D., Mächler, M., Bolker, B. M. & Walker, S. C. Fitting linear mixed-effects 518 models using Ime4. *J. Stat. Softw.* (2015) doi:10.18637/jss.v067.i01.
- 519 37. Costello, S. P. et al. Effect of Fecal Microbiota Transplantation on 8-Week
- 520 Remission in Patients With Ulcerative Colitis. *JAMA* **321**, 156 (2019).
- 521 38. Bolyen, E. *et al.* Reproducible, interactive, scalable and extensible microbiome
  522 data science using QIIME 2. *Nat. Biotechnol.* 37, 852–857 (2019).
- 523 39. Amir, A. *et al.* Deblur Rapidly Resolves Single-Nucleotide Community Sequence
  524 Patterns. *mSystems* 2, (2017).
- 525 40. Bhatt, D. L. & Mehta, C. Adaptive Designs for Clinical Trials. *N. Engl. J. Med.* 375,
  526 65–74 (2016).
- 527 41. Hurlbert, S. H. Pseudoreplication and the Design of Ecological Field Experiments.
  528 *Ecol. Monogr.* 54, 187–211 (1984).
- 529 42. Lazic, S. E., Clarke-Williams, C. J. & Munafò, M. R. What exactly is 'N' in cell 530 culture and animal experiments? *PLOS Biol.* **16**, e2005282 (2018).
- 43. Head, M. L., Holman, L., Lanfear, R., Kahn, A. T. & Jennions, M. D. The Extent
- and Consequences of P-Hacking in Science. *PLOS Biol.* **13**, e1002106 (2015).
- 533
- 534

# 535 FIGURES AND TABLES

#### 537 Table 1: Summary of re-analyses.

Data source	No. patients	No. donors	Evidence for donor superiority? <sup>a</sup>	Evidence for pool superiority? <sup>a</sup>	Association between donor α-diversity and outcomes? <sup>b</sup>	Separation in donor microbiota composition by patient outcome? <sup>c</sup>
Rossen et al.	23	15	No	—	—	—
Moayyedi et al.	38	6	No	—	—	—
Paramsothy et al.	78	14	No	No (0 p.p., 95% CI 0 to 46)	—	—
Costello et al.	38	19	No	No (0 p.p., 95% CI 0 to 74)	_	_
Jacob et al.	20	4	Yes (p = 0.02)	No (88 p.p., 95% CI 0 to 100)	No	No
Pool meta- analysis <sup>‡</sup>	137	36	No	No (41 p.p., 95% CI 0 to 88)	—	—
Goyal et al.	21	21	—	—	No	No
Kump et al.	17	14	—	—	No	No
Vermeire et al.	14	14	—	—	Reported	—
Nishida et al.	41	41	—	—	No	—

p.p.: Percentage points

538 539

540 541 542 a: Tests of donor superiority and pool superiority were using Fisher-Freeman-Halton or Fisher's exact test. Quantifications of pool effect are

differences in clinical efficacy between a very high quality pool (90th percentile) and low quality pool (10th percentile).

b: Using Mann-Whitney U test or Kruskal-Wallis test

543 c: Using PERMANOVA on Bray-Curtis β-diversity

- 545 **Table 2**: Tests of donor superiority, by donor, for Rossen *et al.* Donor labels are
- 546 arbitrary. "Success" means the patient reached the primary endpoint; "failure" means
- 547 they did not.

	Patients treated using this donor		Patients treated not using this donor		Fisher's exact test	
Donor	Success	Failure	Success	Failure	Odds ratio (95% CI)	Mid-p value
А	4	4	3	12	3.7 (0.55 to 29)	0.18
В	1	2	6	14	1.2 (0.03 to 18)	0.89
С	0	2	7	14	0.0 (0.0 to 8)	0.47

548

**Figure 1**: Microbiome analyses for Jacob *et al.* **a** Bacterial  $\alpha$ -diversity of FMT pools do not significantly differ by patient outcomes (p = 0.39, Mann-Whitney *U* test). Each point represents a single patient. **b** Donor microbiota compositions (points; *x*- and *y*coordinates show multidimensional scaling using Bray-Curtis dissimilarity) do not statistically significantly separate by associated patient outcome (color; p = 0.076, PERMANOVA). Each point represents the composition of the pool used to treat an individual patient.



**Figure 2.** Microbiome analyses for Goyal *et al.* **a** Bacterial  $\alpha$ -diversity of FMT pools do not significantly differ by patient outcomes (p = 0.97, Mann-Whitney *U* test). Each point represents a single patient. **b** Donor microbiota compositions (points; *x*- and *y*coordinates show multidimensional scaling using Bray-Curtis dissimilarity) do not statistically significantly separate by associated patient outcome (color; p = 0.70, PERMANOVA). Each point represents the composition of the first sample from the donor used to treat an individual patient.



**Figure 3**: Microbiome analyses for Kump *et al.* **a** Bacterial  $\alpha$ -diversity do not differ by patient outcome (p = 0.39, Kruskal-Wallis test; p > 0.05 for all 3 comparisons, Mann-Whitney *U* test). Each point represents a single patient. The diversity shown for each patient (vertical axis) is the average of the diversity of the sampled FMTs used in that patient. **b** Donor microbiota do not statistically significantly separate by associated patient outcome (color; p = 0.15, PERMANOVA). Each point represents the composition of the first donor sample administered to each patient.



574